Magbiosense, Inc

Website
4340 Duncan Ave
Saint Louis, MO 63110
https://magbiosense.com

MagBiosense, Inc. is a private medical device company based in St. Louis, MO, specializing in the development of innovative diagnostic devices and assays. Their cutting-edge technology offers laboratory-quality sensitivity and the convenience of a point-of-care system, eliminating the need for additional detection steps.

With a focus on infectious diseases like Zika, dengue, and West-Nile viruses, MagBiosense's serological assays have demonstrated significantly higher sensitivity and specificity compared to traditional ELISA methods. Additionally, their high sensitivity detection of cardiac troponin I enables the rapid diagnosis and rule out of heart attacks in emergency departments.

Generated from the website

Also at this address

Own this business?
See a problem?

You might also like

Cadre Bioscience

Cadre Bioscience developing a portfolio of new therapeutics for human diseases of high unmet medical need.

Medical Guidance Systems, LLC

Medical Guidance Systems, LLC, founded in 2013 and based in Saint Louis, MO, specializes in cancer immunotherapy and nanotechnology-enabled drug delivery. The company focuses on developing targeted theragnostic solutions for patients diagnosed with poor prognosis cancers, utilizing proprietary technologies to enhance cancer cell response to treatment. Led by experienced professionals, including founder Dr. Dennis Hallahan and President Stephanie Hallahan, the team is dedicated to advancing cancer care through innovative research and development. Their pipeline includes antibodies and targeted delivery systems aimed at improving therapeutic outcomes for various cancer subtypes. Generated from the website
Blood derivatives

Accuronix Therapeutics Inc

Accuronix Therapeutics Inc is a cutting-edge biotechnology company based in St. Louis, MO, dedicated to developing innovative cancer therapies. Utilizing a unique drug-targeting technology, the company focuses on addressing the most challenging issues in cancer treatment, with an initial emphasis on pancreatic cancer. With strategic partnerships with renowned institutions like Washington University and the University of Pennsylvania, Accuronix Therapeutics aims to develop groundbreaking oncology therapies that selectively target -2 receptors, which are known to be overexpressed on cancer cells. Led by President and CEO Bradley T. Keller, Ph.D., the company is committed to pushing the boundaries of cancer therapy and making a significant impact in the field of oncology.Generated from the website
United States›Missouri›Saint Louis›Magbiosense, Inc

Partial Data by Infogroup (c) 2024. All rights reserved.